Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Laughing Matter: Avanir Resubmits Neurodex NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm is requesting priority review for involuntary emotional expression disorder.

You may also be interested in...



Avanir Could Drop Zenvia Following “Approvable” Letter

Company will meet with FDA to discuss additional safety and efficacy requirements.

Avanir Could Drop Zenvia Following “Approvable” Letter

Company will meet with FDA to discuss additional safety and efficacy requirements.

Neurodex Faces Review Prolongation Due To QT Submission

Priority review of the involuntary emotional expression disorder therapy is extended by 90 days to allow for sufficient consideration of newly submitted data.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel